XORTX Set to Present at Kidney Week 2024 Hosted by ASN

CALGARY, Alberta, Aug. 20, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. XRTX, a trailblazing pharmaceutical company in its late clinical phases, primarily dedicated to crafting novel therapeutic solutions aimed at combating progressive kidney diseases, is delighted to disclose the approval of its presentation at the esteemed American Society of Nephrology - Kidney Week 2024. The company's research and findings in the nephrology field underscore its commitment to addressing chronic kidney issues through advanced treatments. XORTX's focus on innovation is poised to upgrade the clinical practices entailing kidney care, potentially ameliorating patient outcomes significantly.

Progress in Kidney Disease Treatment

XORTX is at the vanguard of pharmaceutical research in kidney disease, having spearheaded numerous studies directed towards the discovery of drugs that can effectively slow down or halt the progression of kidney ailments. Their consistent efforts have culminated in the creation of a pipeline of drugs that represent a beacon of hope for patients grappling with these life-threatening conditions. With the presentation slated for the Kidney Week 2024, the stage is set for XORTX to highlight its transformative research and potentially set new milestones in nephrology care.

Dedication to Advancement in Nephrology

The endorsement from the American Society of Nephrology is indicative of XORTX's stature and credibility within the field. By securing a slot to present at Kidney Week, they have an unrivaled opportunity to showcase their innovative approaches in treating kidney diseases to a global audience. The company's relentless pursuit of excellence in research and development underscores their unwavering commitment to bringing forth cutting-edge treatments that may revolutionize our understanding and management of kidney diseases.

XORTX, ASN, Nephrology